Phase2 Technology Newswire

Phase2 Technology Newswire

Comprehensive Real-Time News Feed for Phase2 Technology.

Results 1 - 20 of 35 in Phase2 Technology

  1. CytRx (CYTR) & Global Blood Therapeutics (GBT) Critical SurveyRead the original story w/Photo

    Thursday Jan 18 | The Breeze

    CytRx and Global Blood Therapeutics are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends. CytRx has higher revenue and earnings than Global Blood Therapeutics.

    Comment?

  2. Head to Head Review: CytRxRead the original story w/Photo

    Tuesday Jan 16 | IntersportsWire

    CytRx and Burcon NutraScience are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability. CytRx has a beta of 2.27, indicating that its share price is 127% more volatile than the S&P 500.

    Comment?

  3. ValuEngine Downgrades CytRx (CYTR) to Strong SellRead the original story w/Photo

    Thursday Jan 4 | The Breeze

    CytRx opened at $1.82 on Friday. The firm has a market cap of $48.37, a price-to-earnings ratio of -1.04 and a beta of 2.27.

    Comment?

  4. CytRx (CYTR) Downgraded by ValuEngineRead the original story w/Photo

    Wednesday Jan 3 | IntersportsWire

    Shares of CytRx traded up $0.06 on Friday, reaching $1.75. The company had a trading volume of 239,800 shares, compared to its average volume of 351,400.

    Comment?

  5. CytRx (CYTR) Stock Rating Lowered by ValuEngineRead the original story w/Photo

    Tuesday Jan 2 | Daily Political

    Shares of CytRx opened at $1.69 on Friday. CytRx has a 52 week low of $1.65 and a 52 week high of $6.00.

    Comment?

  6. Financial Analysis: CytRx (CYTR) vs. Its PeersRead the original story w/Photo

    Dec 11, 2017 | AmericanBankingNews.com

    CytRx is one of 187 publicly-traded companies in the "Biotechnology & Medical Research" industry, but how does it weigh in compared to its competitors? We will compare CytRx to related companies based on the strength of its earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends. CytRx has a beta of 2.26, suggesting that its stock price is 126% more volatile than the S&P 500.

    Comment?

  7. ValuEngine Downgrades CytRx (CYTR) to Strong SellRead the original story w/Photo

    Dec 3, 2017 | AmericanBankingNews.com

    CytRx traded down $0.08 on Friday, hitting $2.10. 168,393 shares of the stock traded hands, compared to its average volume of 318,341.

    Comment?

  8. CytRx (CYTR) Cut to Strong Sell at ValuEngineRead the original story w/Photo

    Dec 1, 2017 | Daily Political

    CytRx opened at $2.10 on Friday. CytRx has a 52 week low of $1.71 and a 52 week high of $6.00.

    Comment?

  9. Critical Comparison: CytRx (CYTR) versus Its CompetitorsRead the original story w/Photo

    Nov 29, 2017 | AmericanBankingNews.com

    CytRx is one of 187 public companies in the "Biotechnology & Medical Research" industry, but how does it compare to its rivals? We will compare CytRx to similar businesses based on the strength of its risk, analyst recommendations, valuation, earnings, dividends, institutional ownership and profitability. CytRx's rivals have higher revenue and earnings than CytRx.

    Comment?

  10. CytRx Highlights Inclusion Of Aldoxorubicin In Pending Upcoming...Read the original story

    Oct 11, 2017 | BioSpace

    The planned clinical trials will enroll patients with cancers that are no longer responding, or never responded, to standard therapy and have progressed. The clinical trials will employ an adaptive design which will allow for expansion of treatment cohorts and modification of patient treatments based on tumor profiling and individual patient responses over time.

    Comment?

  11. Institutional Shareholder Services, Inc., Recommends CytRx...Read the original story

    Oct 3, 2017 | BioSpace

    ISS' experienced research team provides comprehensive proxy analyses and complete vote recommendations for approximately 40,000 meetings annually in around 117 markets worldwide. "The supportive recommendation by ISS adds to the prior positive recommendation by Glass Lewis & Co.

    Comment?

  12. Technical Insights on Biotech Stocks -- Cymabay Therapeutics, Cytori...Read the original story w/Photo

    Oct 3, 2017 | PR Newswire

    If you want a Stock Review on CBAY, CYTX, CYTR, or SRNE then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. On Monday, benchmark US indices were in bullish colors as the NASDAQ Composite closed the trading session up 0.32%; the Dow Jones Industrial Average edged 0.68% higher; and the S&P 500 was up 0.39%.

    Comment?

  13. CytRx Provides Business Update And Highlights Future PlansRead the original story

    Oct 1, 2017 | BioSpace

    During 2017, CytRx has made significant strides in advancing its lead oncology asset aldoxorubicin from a late-stage clinical asset to a partnered, pre-New Drug Application candidate in the U.S. In , the CEO and founder of NantCell, developed, obtained regulatory approval for, and commercialized AbraxaneA , another albumin-mediated cytotoxic agent which currently generates approximately in annual sales. CytRx believes that Dr. Soon-Shiong's track record and expertise with albumin-mediated agents will prove invaluable as NantCell works to obtain regulatory approval for aldoxorubicin, with the goal of commercialization thereafter.

    Comment?

  14. Leading Independent Proxy Advisory Firm Recommends CytRx Stockholders ...Read the original story

    Sep 20, 2017 | BioSpace

    21, 2017 /PRNewswire/ -- CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today announced that Glass Lewis & Co.

    Comment?

  15. CytRx Announces Amendment To Definitive Proxy Statement For Upcoming Special MeetingRead the original story

    Sep 12, 2017 | BioSpace

    CytRx's previous proxy statement dated , had a proposal for a 1-for-6 reverse stock split for its issued and outstanding common stock and a 50% reduction in the authorized shares. CytRx believes that a reverse stock split will enable it to regain compliance with NASDAQ's minimum bid price requirement and maintain its listing on the NASDAQ Capital Market.

    Comment?

  16. CytRx Files Definitive Proxy Statement For Upcoming Special MeetingRead the original story

    Aug 29, 2017 | BioSpace

    The Company is requesting that stockholders vote on a single proposal which will include authorizing the Board of Directors to effect a 1-for-6 reverse stock split of the Company's issued and outstanding common stock. CytRx believes that a reverse stock split will enable it to regain compliance with NASDAQ's minimum bid price requirement and maintain its listing on the NASDAQ Capital Market.

    Comment?

  17. CytRx Announces Receipt Of NASDAQ Listing DeterminationRead the original story

    Aug 24, 2017 | BioSpace

    At the hearing, the Company will present its plan to regain compliance with the bid price requirement, which will be based upon a reverse stock split. The Company filed a preliminary proxy statement with the Securities and Exchange Commission on to stockholders who owned common stock as of the record date.

    Comment?

  18. CytRx Files Preliminary Proxy Statement For Upcoming Special MeetingRead the original story

    Aug 20, 2017 | BioSpace

    A reverse stock split may enable the Company to regain compliance with NASDAQ's CytRx's intent is to continue to be listed on the NASDAQ Capital Market. In addition to sustaining a NASDAQ listing, the Company believes a higher share price resulting from a reverse stock split will help enlarge the shareholder base by expanding its appeal to institutional investors and as a result enhance long-term stockholder value.

    Comment?

  19. CytRx (CYTR) and OncoMed Pharmaceuticals (NASDAQ:OMED) Head-To-Head SurveyRead the original story w/Photo

    Aug 12, 2017 | IntersportsWire

    CytRx and OncoMed Pharmaceuticals are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, earnings, risk, valuation, institutional ownership and profitability. 11.4% of CytRx shares are owned by institutional investors.

    Comment?

  20. CytRx out-licenses aldoxorubicin to NantCell in deal worth up to $356MRead the original story w/Photo

    Jul 28, 2017 | Seeking Alpha

    Nano cap CytRx is up 2% premarket on light volume on the heels of its announcement that it has inked a global license deal with NantWorks subsidiary NantCell to develop and commercialize aldoxorubicin for all indications. Under the terms of the agreement, NantCell will purchase $13M of CytRx common stock at $1.10 per share and will receive a warrant to purchase up the 3M shares of common at $1.10 over the next 18 months.

    Comment?